Cytokine Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Chronic Diseases and Growing Biologics Domain
The cytokine market is estimated to be valued at USD 90.84 Bn in 2024, exhibiting a CAGR of 8.6% over the forecast period (2024-2031). Development of novel therapies for autoimmune diseases and high adoption of targeted therapies have fueled the market growth.
Market Dynamics:
The growth of the cytokine market is driven by the increasing prevalence of chronic diseases and growing biologics domain. One of the key drivers is the rising number of chronic diseases globally. According to data published by WHO in 2022, chronic diseases accounted for 71% of global deaths in 2021. Cytokines play a crucial role in the treatment of various chronic diseases like cancer and autoimmune disorders. The growing burden of chronic diseases has raised the demand for cytokines. Furthermore, the expanding biologics sector is also boosting the market growth. Biologics have revolutionized the treatment of various critical diseases. Cytokines find widespread application in biologic drug manufacturing and research activities. However, high costs associated with cytokine therapeutics and stringent regulatory framework pose challenges to market players.
Increased Focus on Cancer Research and Development Drives Demand
Cancer continues to pose a significant health burden globally. With rising cancer incidence, research activities focused on developing effective treatment options have increased considerably. Cytokines play a pivotal role in modulating the immune system's response to fight cancer cells. As a result, cytokine-based therapies have gained significant attention from pharmaceutical companies and research institutes in recent years. The approval and commercialization of several cancer immunotherapy drugs targeting cytokines are expected to augment the cytokine market size during the forecast period.
Advancements in Recombinant DNA Technology is Enabling the Production of Novel Cytokines
The cytokine market has evolved significantly over the past few decades driven by technological advancements, especially in the field of recombinant DNA technology. Earlier, isolating cytokines from natural sources was challenging and produced very low yields. Recombinant DNA techniques have enabled mass production of cytokines in microbial systems like yeast, E. coli or mammalian expression systems like Chinese hamster ovary (CHO) cells. This has supported researchers and pharmaceutical companies in developing a wide range of novel cytokine therapeutics for various disease indications. Ongoing R&D for engineering novel cytokines with enhanced stability and therapeutic properties through genetic and protein engineering technologies will likely open up new avenues of growth for market players.
High Cost of Developing and Manufacturing Cytokine Therapeutics Acts as a Barrier
Developing an effective cytokine-based therapy requires extensive research spanning several phases of pre-clinical and clinical testing to establish safety and efficacy. This prolonged research and development process makes cytokine drugs highly capital-intensive endeavors. Manufacturing cytokines also poses technical challenges associated with achieving proper post-translational processing, purification, and quality control. The high costs of setting up facilities compliant with Current Good Manufacturing Practice (CGMP) guidelines for manufacturing cytokines increases the financial risk. Additional costs are incurred in distributing the perishable biologics with a stringent cold chain. These economic factors negatively impact market growth up to some extent.
Stringent Regulatory Approvals Delay the Commercialization of New Cytokine Products
Regulatory bodies worldwide have implemented stringent guidelines for evaluating the quality, safety, and efficacy of cytokine therapies due to their novel mechanism of action and potential side effects. Obtaining regulatory clearances from agencies like U.S. Food and Drug Administration and European Medicine Agency involves demonstrating complex clinical data through different phases of trials over many years. Any delay in approval prolongs the time taken by pharmaceutical companies to commercially launch new cytokine products. The costly, time-consuming approval process acts as a bottleneck, deterring smaller companies from pursuing cytokine drug development. Though necessary to ensure patient safety, cumbersome regulations can hinder faster market adoption of promising cytokine therapies.
Personalized Medicine Approach Offers Lucrative Opportunities
The 'one-size-fits-all' treatment approach has limitations in oncology. Cytokines show varying therapeutic responses based on a patient's genetic profile and tumor characteristics. Hence, a momentum is building towards developing personalized cytokine therapies tailored to an individual's needs. Combining cytokine drugs with companion diagnostics to identify predictive biomarkers can optimize clinical outcomes. Major pharmaceutical players are making investments in companion diagnostic tests to expand the use of already approved cytokine drugs to new patient subsets. The personalized medicine approach opens up opportunities for co-development of predictive tests along with customized cytokine therapies.
Opportunities in Non-oncology Segments like Immunodeficiency Disorders
While cancer research continues to drive most of the cytokine drug sales, opportunities exists in expanding therapeutic applications to other clinical areas like immunodeficiency disorders, organ transplant rejection, and rare genetic diseases. Developing cytokine therapies for conditions like severe combined immunodeficiency (SCID) where the immune system is not functioning properly can help address unmet medical needs. Partnering with patient advocacy groups and conducting additional trials can facilitate clinical uptake of cytokine drugs for non-oncology uses. This presents promising avenues for market players to diversify beyond oncology.
b https://www.coherentmarketinsights.com/market-insight/cytokine-market-5238
Key Developments
- On October 22, 2024, UTHealth School of Dentistry, a university in Texas, U.S., announced a multidiscipline collaboration to investigate micro-cytokine factories, to investigate a novel micro-cytokine factory platform for the treatment of periodontal disease and oral cancer
- On September 16, 2024, ScaleReady, a provider of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform, Bio-Techne, a global biotechnology company, announced the launch of the G-Rex optimized ProPak GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing. The ProPak GMP Cytokine product consists of a weldable bag filled with liquid formulated GMP-grade cytokines, specifically interleukin-7 (IL-7) or interleukin-15 (IL-15), commonly used in the ex vivo manufacturing of CAR-T and TCR-T cells.
- On January 29, 2024, Synthekine Inc., an engineered cytokine therapeutics company, announced a worldwide collaboration with Sanofi, a biopharmaceutical company, to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. IL-10 is an important immune-regulatory cytokine that attracted substantial clinical interest in the past for use as an immunosuppressive agent.
Key Players
Abbott, AB Sciex, Agilent Technologies Inc., bioMerieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Quest Diagnostics Inc, Danaher, DiaSorin S.p.A, Immunodiagnostic Systems, and Fujirebio, Inc.
